NASDAQ:RXII - RXi Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$0.4560Today's Range$0.4550 - $0.4852-Week Range$0.31 - $7.70Volume199,686 shsAverage Volume1.73 million shsMarket Capitalization$2.00 millionP/E RatioN/ADividend YieldN/ABeta2.07 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. RXi Pharmaceuticals Corporation has collaborations with the Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; PCI Biotech; and Karolinska Institutet. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. Receive RXII News and Ratings via Email Sign-up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RXII Previous Symbol CUSIPN/A CIK1533040 Webhttp://www.rxipharma.com/ Phone508-767-3861Debt Debt-to-Equity RatioN/A Current Ratio1.77 Quick Ratio1.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($4.20) Net Income$-12,450,000.00 Net Margins-4,990.20% Return on Equity-412.15% Return on Assets-179.54%Miscellaneous EmployeesN/A Outstanding Shares4,380,000Market Cap$2.00 million Next Earnings DateN/A OptionableNot Optionable RXi Pharmaceuticals (NASDAQ:RXII) Frequently Asked Questions What is RXi Pharmaceuticals' stock symbol? RXi Pharmaceuticals trades on the NASDAQ under the ticker symbol "RXII." When did RXi Pharmaceuticals' stock split? How did RXi Pharmaceuticals' stock split work? RXi Pharmaceuticals's stock reverse split before market open on Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of RXi Pharmaceuticals stock prior to the reverse split would have 10 shares after the split. How were RXi Pharmaceuticals' earnings last quarter? RXi Pharmaceuticals Corp (NASDAQ:RXII) issued its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.16. The biotechnology company had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.02 million. RXi Pharmaceuticals had a negative net margin of 4,990.20% and a negative return on equity of 412.15%. View RXi Pharmaceuticals' Earnings History. What price target have analysts set for RXII? 1 Wall Street analysts have issued twelve-month price objectives for RXi Pharmaceuticals' shares. Their predictions range from $3.00 to $3.00. On average, they anticipate RXi Pharmaceuticals' share price to reach $3.00 in the next twelve months. View Analyst Price Targets for RXi Pharmaceuticals. What is the consensus analysts' recommendation for RXi Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RXi Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for RXi Pharmaceuticals. Has RXi Pharmaceuticals been receiving favorable news coverage? News stories about RXII stock have trended somewhat positive recently, InfoTrie reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. RXi Pharmaceuticals earned a coverage optimism score of 1.9 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of RXi Pharmaceuticals' key competitors? Some companies that are related to RXi Pharmaceuticals include Flex Pharma (FLKS), Synergy Pharmaceuticals (SGYP), Ritter Pharmaceuticals (RTTR), NeuroVive Pharmaceutical (NEVPF), International Stem Cell (ISCO), Achaogen (AKAO), Parnell Pharmaceuticals (PARNF), Endonovo Therapeutics (ENDV), Praxsyn (PXYN), Uluru (ULUR), DelMar Pharmaceuticals (DMPI), Stellar Biotechnologies (SBOT), Innovus Pharmaceuticals (INNV), iCo Therapeutics (ICOTF) and Innovus Pharmaceuticals (INNVD). What other stocks do shareholders of RXi Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other RXi Pharmaceuticals investors own include Rigel Pharmaceuticals (RIGL), Idera Pharmaceuticals (IDRA), Novavax (NVAX), Anavex Life Sciences (AVXL), Auris Medical (EARS), Endologix (ELGX), Synergy Pharmaceuticals (SGYP), Protalix Biotherapeutics (PLX), Genocea Biosciences (GNCA) and Micron Technology (MU). Who are RXi Pharmaceuticals' key executives? RXi Pharmaceuticals' management team includes the folowing people: Dr. Geert Cauwenbergh, Pres, CEO, Acting CFO & Director (Age 64)Dr. Gerrit Dispersyn Dr. Med. Sc, Chief Devel. Officer (Age 43)Ms. Caitlin Kontulis, Sr. Director of Fin. & Sec. (Age 32)Dr. Karen Bulock, Former VP of Research How do I buy shares of RXi Pharmaceuticals? Shares of RXII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. How big of a company is RXi Pharmaceuticals? RXi Pharmaceuticals has a market capitalization of $0.00 and generates $10,000.00 in revenue each year. The biotechnology company earns $-12,450,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis. What is RXi Pharmaceuticals' official website? The official website for RXi Pharmaceuticals is http://www.rxipharma.com/. How can I contact RXi Pharmaceuticals? RXi Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The biotechnology company can be reached via phone at 508-767-3861 or via email at [email protected] MarketBeat Community Rating for RXi Pharmaceuticals (NASDAQ RXII)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 157 (Vote Outperform)Underperform Votes: 162 (Vote Underperform)Total Votes: 319MarketBeat's community ratings are surveys of what our community members think about RXi Pharmaceuticals and other stocks. Vote "Outperform" if you believe RXII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RXII will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: What is the 52-week high/low? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.